ArticleCancer chemotherapy and pharmacology2016

A phase 1 dose-escalation study of NEO-102 in patients with refractory colon and pancreatic cancer.

Muhammad S Beg et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.